Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508060 | 0.79 | MAPT (0.51) | NPC1RAB9AKMT2AMAPK14MAPK13 | |
| SCHEMBL508061 | 0.79 | MAPT (0.51) | NPC1RAB9AKMT2AMAPK14MAPK13 | |
| SCHEMBL10188917 | 0.73 | EGFR (0.39) | NPC1RAB9AKMT2ANPSR1RXFP1 | |
| SCHEMBL10188921 | 0.67 | MAPT (0.59) | NPC1RAB9AKMT2AMAPK14MAPK13 | |
| SCHEMBL19390191 | 0.66 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL29022475 | 0.65 | RELA (0.56) | ALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL30987464 | 0.65 | RELA (0.56) | ALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL10188918 | 0.63 | LCK (0.66) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL772846 | 0.63 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL27562366 | 0.61 | MAPK14 (0.56) | KMT2AMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | MAP3K20, MAP3K6, MAP3K19 | NPC1 2962/4885RAB9A 2042/4885KMT2A 509/4885 |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | MAP3K20, MAP3K6, MAP3K19 | NPC1 2962/4885RAB9A 2042/4885KMT2A 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.